Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares (2)
10 november, 21:23
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Jacob Jelsing | |
2. | Reason for the notification | ||
a) | Position/status | Board member in Gubra | |
b) | Initial notification/ Amendment | Initial notification | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Gubra A/S | |
b) | LEI | 254900T17RRFZONO6W53 | |
4.1 | Details of the transaction(s): | ||
a) | Description of the financial instrument, type of instrument
Identification code | Shares
ISIN DK0062266474 | |
b) | Nature of the transaction | Purchase | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
DKK 387.82
DKK 385.00 DKK 383.00 DKK 380.00 DKK 389.98 | 10,000
10,000 6,000 2,792 10,000 | ||
d) | Aggregated information
— Aggregated volume — Price | Average price per share: DKK 386.34
Total number of shares: 38,792 Total price: DKK 14,987,001 | |
e) | Date of the transaction | 7 November 2025 and 10 November 2025 | |
f) | Place of the transaction | NASDAQ Copenhagen |
Contacts at Gubra
Media: Sofia Pitt Boserup (sbo@gubra.dk, +45 4188 9586)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 275 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.
Ämnen i artikeln
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares (2)
10 november, 21:23
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Jacob Jelsing | |
2. | Reason for the notification | ||
a) | Position/status | Board member in Gubra | |
b) | Initial notification/ Amendment | Initial notification | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Gubra A/S | |
b) | LEI | 254900T17RRFZONO6W53 | |
4.1 | Details of the transaction(s): | ||
a) | Description of the financial instrument, type of instrument
Identification code | Shares
ISIN DK0062266474 | |
b) | Nature of the transaction | Purchase | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
DKK 387.82
DKK 385.00 DKK 383.00 DKK 380.00 DKK 389.98 | 10,000
10,000 6,000 2,792 10,000 | ||
d) | Aggregated information
— Aggregated volume — Price | Average price per share: DKK 386.34
Total number of shares: 38,792 Total price: DKK 14,987,001 | |
e) | Date of the transaction | 7 November 2025 and 10 November 2025 | |
f) | Place of the transaction | NASDAQ Copenhagen |
Contacts at Gubra
Media: Sofia Pitt Boserup (sbo@gubra.dk, +45 4188 9586)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 275 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.
Ämnen i artikeln
Analys
Saab kammar hem miljardordrar
Guldrallyt
Fonder
Bolån
Analys
Saab kammar hem miljardordrar
Guldrallyt
Fonder
Bolån
Marknadsöversikt
1 DAG %
Senast
1 mån
